Grazoprevir + Elbasvir

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Hepatitis CHepatitis C Infection

Phase 3

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

CompletedNCT02105701

Merck Sharp & Dohme LLCHepatitis C Infection

Start: 2014-06-05End: 2015-06-19Updated: 2021-02-05

Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)

CompletedNCT02252016

Merck Sharp & Dohme LLCHepatitis C

Start: 2014-10-22End: 2016-06-14Updated: 2018-10-03

Related Papers

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.

2018-01-1736 citations

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection

Hepatology Communications2017-08-229 citations

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.

2017-02-1159 citations

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.

2016-10-05123 citations